Hepatitis Monthly

Published by: Kowsar

Hepatic Failure After Bariatric Surgery: A Systematic Review

Behrouz Keleidari 1 , Mohsen Mahmoudieh 1 , Khadije Gorgi 2 , * , Erfan Sheikhbahaei 3 and Shahab Shahabi 1
Authors Information
1 Fellowship of Minimally Invasive and Obesity Surgery, Minimally Invasive Surgery and Obesity Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2 Minimally Invasive Surgery and Obesity Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
3 Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Hepatitis Monthly: January 31, 2019, 19 (1); e86078
  • Published Online: February 3, 2019
  • Article Type: Review Article
  • Received: November 4, 2018
  • Revised: January 5, 2019
  • Accepted: January 18, 2019
  • DOI: 10.5812/hepatmon.86078

To Cite: Keleidari B, Mahmoudieh M, Gorgi K, Sheikhbahaei E, Shahabi S. Hepatic Failure After Bariatric Surgery: A Systematic Review, Hepat Mon. 2019 ; 19(1):e86078. doi: 10.5812/hepatmon.86078.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
5. Conclusions
Footnotes
References
  • 1. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012. [PubMed: 25920090].
  • 2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431. [PubMed: 26707365].
  • 3. Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: Clinical aspects and current management strategies. Clin Obes. 2014;4(5):243-53. doi: 10.1111/cob.12068. [PubMed: 25825857].
  • 4. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5-10. doi: 10.1097/01.mcg.0000168638.84840.ff. [PubMed: 16540768].
  • 5. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367. [PubMed: 28714183].
  • 6. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396-402. doi: 10.1016/j.cgh.2008.08.012. [PubMed: 18986848].
  • 7. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;(1). CD007340. doi: 10.1002/14651858.CD007340.pub2. [PubMed: 20091629].
  • 8. Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, et al. Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280-9. doi: 10.1007/s11695-015-1691-x. [PubMed: 25917981].
  • 9. Mahawar KK, Parmar C, Graham Y, De Alwis N, Carr WR, Jennings N, et al. Monitoring of liver function tests after Roux-en-Y gastric bypass: An examination of evidence base. Obes Surg. 2016;26(10):2516-22. doi: 10.1007/s11695-016-2280-3. [PubMed: 27381560].
  • 10. Cazzo E, Pareja JC, Chaim EA. Liver failure following biliopancreatic diversions: A narrative review. Sao Paulo Med J. 2017;135(1):66-70. doi: 10.1590/1516-3180.2016.0129220616. [PubMed: 28380179].
  • 11. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012. [PubMed: 26823198].
  • 12. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-725 e6. doi: 10.1053/j.gastro.2012.02.003. [PubMed: 22326434].
  • 13. Gan SK, Watts GF. Is adipose tissue lipolysis always an adaptive response to starvation?: Implications for non-alcoholic fatty liver disease. Clin Sci (Lond). 2008;114(8):543-5. doi: 10.1042/CS20070461. [PubMed: 18181765].
  • 14. Duseja A, Chawla YK. Obesity and NAFLD: The role of bacteria and microbiota. Clin Liver Dis. 2014;18(1):59-71. doi: 10.1016/j.cld.2013.09.002. [PubMed: 24274865].
  • 15. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: A microbiota-driven disease. Trends Endocrinol Metab. 2013;24(11):537-45. doi: 10.1016/j.tem.2013.05.009. [PubMed: 23827477].
  • 16. Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33(3):128-33. doi: 10.1097/MOG.0000000000000349. [PubMed: 28257306]. [PubMed Central: PMC5662009].
  • 17. Wu X, Tian Z. Gut-liver axis: Gut microbiota in shaping hepatic innate immunity. Sci China Life Sci. 2017;60(11):1191-6. doi: 10.1007/s11427-017-9128-3. [PubMed: 28840534].
  • 18. Sabate JM, Jouet P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg. 2008;18(4):371-7. doi: 10.1007/s11695-007-9398-2. [PubMed: 18286348].
  • 19. Elnahas A, Nguyen GC, Okrainec A, Quereshy F, Jackson TD. The effect of underlying liver disease on short-term outcomes following bariatric surgery. Surg Endosc. 2014;28(9):2708-12. doi: 10.1007/s00464-014-3532-8. [PubMed: 24737534].
  • 20. Weingarten TN, Swain JM, Kendrick ML, Charlton MR, Schroeder BJ, Lee RE, et al. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg. 2011;21(11):1714-20. doi: 10.1007/s11695-011-0521-z. [PubMed: 21948267].
  • 21. Ribeireiro T, Swain J, Sarr M, Kendrick M, Que F, Sanderson S, et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011;21(3):310-5. doi: 10.1007/s11695-010-0228-6. [PubMed: 20922498].
  • 22. Benotti P, Wood GC, Winegar DA, Petrick AT, Still CD, Argyropoulos G, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259(1):123-30. doi: 10.1097/SLA.0b013e31828a0ee4. [PubMed: 23470583]. [PubMed Central: PMC4075503].
  • 23. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017-23. doi: 10.1007/s10620-013-2743-5. [PubMed: 23775317].
  • 24. Goossens N, Hoshida Y, Song WM, Jung M, Morel P, Nakagawa S, et al. Nonalcoholic steatohepatitis is associated with increased mortality in obese patients undergoing bariatric surgery. Clin Gastroenterol Hepatol. 2016;14(11):1619-28. doi: 10.1016/j.cgh.2015.10.010. [PubMed: 26492845]. [PubMed Central: PMC4838546].
  • 25. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97 e10. doi: 10.1053/j.gastro.2015.04.043. [PubMed: 25935633]. [PubMed Central: PMC4516664].
  • 26. Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun. 2017;1(5):421-8. doi: 10.1002/hep4.1054. [PubMed: 29404470]. [PubMed Central: PMC5721410].
  • 27. Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016. Dig Dis Sci. 2016;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. [PubMed: 27017224].
  • 28. Verna EC. Liver biopsy at the time of bariatric surgery: A benefit for patients and the medical community. Semin Liver Dis. 2014;34(1):1-6. doi: 10.1055/s-0034-1371549. [PubMed: 24782252].
  • 29. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11(1):25-35. viii. doi: 10.1016/j.cld.2007.02.004. [PubMed: 17544970].
  • 30. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. doi: 10.1002/hep.21496. [PubMed: 17393509].
  • 31. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103(7):1682-8. doi: 10.1111/j.1572-0241.2008.01933.x. [PubMed: 18616651].
  • 32. Cazzo E, Jimenez LS, Pareja JC, Chaim EA. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: A prospective study. Obes Surg. 2015;25(6):982-5. doi: 10.1007/s11695-014-1489-2. [PubMed: 25381118].
  • 33. Qureshi K, Clements RH, Abrams GA. The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obes Surg. 2008;18(3):264-70. doi: 10.1007/s11695-007-9295-8. [PubMed: 18214632].
  • 34. Sugerman HJ, Kellum JM, DeMaria EJ. Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity. J Gastrointest Surg. 1997;1(6):517-24. discussion 524-6. doi: 10.1016/S1091-255X(97)80067-4. [PubMed: 9834387].
  • 35. Murr MM, Balsiger BM, Kennedy FP, Mai JL, Sarr MG. Malabsorptive procedures for severe obesity: comparison of pancreaticobiliary bypass and very very long limb Roux-en-Y gastric bypass. J Gastrointest Surg. 1999;3(6):607-12. doi: 10.1016/S1091-255X(99)80082-1. [PubMed: 10554367].
  • 36. Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, Molly McMahon M, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis. 2013;9(2):159-91. doi: 10.1016/j.soard.2012.12.010. [PubMed: 23537696].
  • 37. Patel S, Szomstein S, Rosenthal RJ. Reasons and outcomes of reoperative bariatric surgery for failed and complicated procedures (excluding adjustable gastric banding). Obes Surg. 2011;21(8):1209-19. doi: 10.1007/s11695-010-0234-8. [PubMed: 20676940].
  • 38. Eilenberg M, Langer FB, Beer A, Trauner M, Prager G, Staufer K. Significant liver-related morbidity after bariatric surgery and its reversal-a case series. Obes Surg. 2018;28(3):812-9. doi: 10.1007/s11695-017-2925-x. [PubMed: 28965313]. [PubMed Central: PMC5803276].
  • 39. Genser L, Soprani A, Tabbara M, Siksik JM, Cady J, Carandina S. Laparoscopic reversal of mini-gastric bypass to original anatomy for severe postoperative malnutrition. Langenbecks Arch Surg. 2017;402(8):1263-70. doi: 10.1007/s00423-017-1615-4. [PubMed: 28803414].
  • 40. Shimizu H, Annaberdyev S, Motamarry I, Kroh M, Schauer PR, Brethauer SA. Revisional bariatric surgery for unsuccessful weight loss and complications. Obes Surg. 2013;23(11):1766-73. doi: 10.1007/s11695-013-1012-1. [PubMed: 23828032].
  • 41. Kermansaravi M, Abdolhosseini MR, Kabir A, Pazouki A. Severe hypoalbuminemia and steatohepatitis leading to death in a young vegetarian female, 8 months after mini gastric bypass: A case report. Int J Surg Case Rep. 2017;31:17-9. doi: 10.1016/j.ijscr.2016.12.004. [PubMed: 28088126]. [PubMed Central: PMC5233785].
  • 42. Motamedi MAK, Barzin M, Ebrahimi M, Ebrahimi R, Khalaj A. Severe fatal protein malnutrition and liver failure in a morbidly obese patient after mini-gastric bypass surgery: Case report. Int J Surg Case Rep. 2017;33:71-4. doi: 10.1016/j.ijscr.2017.02.033. [PubMed: 28282599]. [PubMed Central: PMC5344219].
  • 43. Langdon DE, Leffingwell T, Rank D. Hepatic failure after biliopancreatic diversion. Am J Gastroenterol. 1993;88(2):321. [PubMed: 8424445].
  • 44. Mayo Ossorio MA, Pacheco Garcia JM, Pérez Gomar D, Bazán Hinojo Mdel C, Vilchez Lopez FJ, Aguilar Diosdad M, et al. [Long-term fulminant hepatic failure in patients undergoing gastric bypass for morbid obesity]. Nutr Hosp. 2015;32(1):430-4. Spanish. doi: 10.3305/nh.2015.32.1.9174. [PubMed: 26262750].
  • 45. Lammers WJ, van Tilburg AJ, Apers JA, Wiebolt J. Liver failure caused by prolonged state of malnutrition following bariatric surgery. World J Hepatol. 2018;10(3):396-9. doi: 10.4254/wjh.v10.i3.396. [PubMed: 29599903]. [PubMed Central: PMC5871860].
  • 46. Buhmann H, Vines L, Schiesser M. Operative strategies for patients with failed primary bariatric procedures. Dig Surg. 2014;31(1):60-6. doi: 10.1159/000358537. [PubMed: 24819499].
  • 47. Brethauer SA, Kothari S, Sudan R, Williams B, English WJ, Brengman M, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952-72. doi: 10.1016/j.soard.2014.02.014. [PubMed: 24776071].
  • 48. World Health Organisation. Obesity and overweight fact sheet. 2017.
  • 49. Fuchs HF, Broderick RC, Harnsberger CR, Chang DC, Sandler BJ, Jacobsen GR, et al. Benefits of bariatric surgery do not reach obese men. J Laparoendosc Adv Surg Tech A. 2015;25(3):196-201. doi: 10.1089/lap.2014.0639. [PubMed: 25654317].
  • 50. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291-326. doi: 10.1007/s12325-017-0556-1. [PubMed: 28526997]. [PubMed Central: PMC5487879].
  • 51. Marinou K, Adiels M, Hodson L, Frayn KN, Karpe F, Fielding BA. Young women partition fatty acids towards ketone body production rather than VLDL-TAG synthesis, compared with young men. Br J Nutr. 2011;105(6):857-65. doi: 10.1017/S0007114510004472. [PubMed: 21251339].
  • 52. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: A novel hepato-ovarian axis? Endocrine. 2016;51(2):211-21. doi: 10.1007/s12020-015-0640-8. [PubMed: 26024975].
  • 53. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12(2):224-9. doi: 10.1016/0168-8278(91)90942-5. [PubMed: 2051001].
  • 54. Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragon-Alonso A, Pascual-Diaz M, et al. Obesity and inflammation: Change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950-5. doi: 10.1007/s11695-012-0643-y. [PubMed: 22527592].
  • 55. Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointestin Liver Dis. 2006;15(4):363-73. [PubMed: 17205149].
  • 56. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res. 2004;12(6):962-71. doi: 10.1038/oby.2004.118. [PubMed: 15229336].
  • 57. Delhanty PJ, van der Lely AJ. Ghrelin: A new treatment for non-alcoholic fatty liver disease? Endocrine. 2013;43(2):247-8. doi: 10.1007/s12020-012-9800-2. [PubMed: 22992889].
  • 58. Keleidari B, Mohammadi Mofrad R, Shahabi Shahmiri S, Sanei MH, Kolahdouzan M, Sheikhbahaei E. The impacts of gastroileostomy rat model on glucagon-like peptide-1: A promising model to control type 2 diabetes mellitus. Obes Surg. 2018;28(10):3246-52. doi: 10.1007/s11695-018-3312-y. [PubMed: 29785472].
  • 59. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007;17(9):1193-8. doi: 10.1007/s11695-007-9211-2. [PubMed: 18074494].
  • 60. Cazzo E, Pareja JC, Chaim EA, Geloneze B, Barreto MR, Magro DO. GLP-1 and GLP-2 levels are correlated with satiety regulation after Roux-en-Y gastric bypass: results of an exploratory prospective study. Obes Surg. 2017;27(3):703-8. doi: 10.1007/s11695-016-2345-3. [PubMed: 27565666].
  • 61. Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 2009;137(3):997-1005. 1005 e1-4. doi: 10.1053/j.gastro.2009.05.051. [PubMed: 19482026].
  • 62. Holst JJ, Madsbad S, Bojsen-Moller KN, Svane MS, Jorgensen NB, Dirksen C, et al. Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surg Obes Relat Dis. 2018;14(5):708-14. doi: 10.1016/j.soard.2018.03.003. [PubMed: 29776493]. [PubMed Central: PMC5974695].
  • 63. Stefanidis A, Oldfield BJ. Neuroendocrine mechanisms underlying bariatric surgery: Insights from human studies and animal models. J Neuroendocrinol. 2017;29(10). doi: 10.1111/jne.12534. [PubMed: 28887853].
  • 64. Laferrere B. Bariatric surgery and obesity: Influence on the incretins. Int J Obes Suppl. 2016;6(Suppl 1):S32-6. doi: 10.1038/ijosup.2016.8. [PubMed: 28685028]. [PubMed Central: PMC5485883].
  • 65. Dimitriadis GK, Randeva MS, Miras AD. Potential hormone mechanisms of bariatric surgery. Curr Obes Rep. 2017;6(3):253-65. doi: 10.1007/s13679-017-0276-5. [PubMed: 28780756]. [PubMed Central: PMC5585994].
  • 66. Mahawar KK, Kumar P, Parmar C, Graham Y, Carr WR, Jennings N, et al. Small bowel limb lengths and Roux-en-Y gastric bypass: A systematic review. Obes Surg. 2016;26(3):660-71. doi: 10.1007/s11695-016-2050-2. [PubMed: 26749410].
  • 67. Disse E, Pasquer A, Espalieu P, Poncet G, Gouillat C, Robert M. Greater weight loss with the omega loop bypass compared to the Roux-en-Y gastric bypass: A comparative study. Obes Surg. 2014;24(6):841-6. doi: 10.1007/s11695-014-1180-7. [PubMed: 24442421].
  • 68. Kruschitz R, Luger M, Kienbacher C, Trauner M, Klammer C, Schindler K, et al. The effect of Roux-en-Y vs. omega-loop gastric bypass on liver, metabolic parameters, and weight loss. Obes Surg. 2016;26(9):2204-12. doi: 10.1007/s11695-016-2083-6. [PubMed: 27003699]. [PubMed Central: PMC4985536].
  • 69. Spivak H, Munz Y, Rubin M, Raz I, Shohat T, Blumenfeld O. Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: A registry-based comprehensive first-year analysis. Surg Obes Relat Dis. 2018;14(2):175-80. doi: 10.1016/j.soard.2017.11.006. [PubMed: 29217131].
  • 70. Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Laparoscopic mini-gastric bypass: Experience with tailored bypass limb according to body weight. Obes Surg. 2008;18(3):294-9. doi: 10.1007/s11695-007-9367-9. [PubMed: 18193178].
  • 71. Mahawar KK, Parmar C, Carr WRJ, Jennings N, Schroeder N, Small PK. Impact of biliopancreatic limb length on severe protein-calorie malnutrition requiring revisional surgery after one anastomosis (mini) gastric bypass. J Minim Access Surg. 2018;14(1):37-43. doi: 10.4103/jmas.JMAS_198_16. [PubMed: 28695878]. [PubMed Central: PMC5749196].
  • 72. Hess DS. Limb measurements in duodenal switch. Obes Surg. 2003;13(6):966. doi: 10.1381/096089203322618885. [PubMed: 14738693].
  • 73. Jan A, Narwaria M, Mahawar KK. A systematic review of bariatric surgery in patients with liver cirrhosis. Obes Surg. 2015;25(8):1518-26. doi: 10.1007/s11695-015-1727-2. [PubMed: 25982807].
  • 74. Suraweera D, Dutson E, Saab S. Liver transplantation and bariatric surgery: Best approach. Clin Liver Dis. 2017;21(2):215-30. doi: 10.1016/j.cld.2016.12.001. [PubMed: 28364810].
  • 75. Patel YA, Berg CL, Moylan CA. Liver transplantation for nonalcoholic fatty liver disease: Role of bariatric surgery for comorbid obesity. J Adv Nutr Hum Metab. 2016;2. e1327. doi: 10.14800/janhm.1327.
  • 76. D'Albuquerque LA, Gonzalez AM, Wahle RC, de Oliveira Souza E, Mancero JM, de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl. 2008;14(6):881-5. doi: 10.1002/lt.21472. [PubMed: 18508357].
  • 77. Lazzati A, Iannelli A, Schneck AS, Nelson AC, Katsahian S, Gugenheim J, et al. Bariatric surgery and liver transplantation: A systematic review a new frontier for bariatric surgery. Obes Surg. 2015;25(1):134-42. doi: 10.1007/s11695-014-1430-8. [PubMed: 25337867].
  • 78. Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver transplantation and bariatric surgery: Timing and outcomes. Liver Transpl. 2018;24(9):1280-7. doi: 10.1002/lt.25303. [PubMed: 30080949].
  • 79. Buchman AL, Naini BV, Spilker B. The differentiation of intestinal-failure-associated liver disease from nonalcoholic fatty liver and nonalcoholic steatohepatitis. Semin Liver Dis. 2017;37(1):33-44. doi: 10.1055/s-0036-1597771. [PubMed: 28201847].
  • 80. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: Pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013;4(5):223-31. doi: 10.1177/2040622313496126. [PubMed: 23997926]. [PubMed Central: PMC3752184].
  • 81. Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-90. doi: 10.3748/wjg.v16.i24.2978. [PubMed: 20572300]. [PubMed Central: PMC2890937].
  • 82. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18(3):349-58. doi: 10.1517/13543780902780175. [PubMed: 19243285].
  • 83. Miazga A, Osinski M, Cichy W, Zaba R. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci. 2015;60(1):118-24. doi: 10.1016/j.advms.2014.09.001. [PubMed: 25657082].
  • 84. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-8. doi: 10.1016/j.cgh.2009.12.022. [PubMed: 20060064].
  • 85. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380-6. doi: 10.1111/j.1365-2362.2010.02419.x. [PubMed: 21128930].
  • 86. Hamvas J. [Proton-pump inhibitor therapy and small bowel bacterial contamination]. Orv Hetil. 2012;153(33):1287-93. Hungarian. doi: 10.1556/OH.2012.29419. [PubMed: 22890175].
  • 87. Ratuapli SK, Ellington TG, O'Neill MT, Umar SB, Harris LA, Foxx-Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730-5. doi: 10.1038/ajg.2012.4. [PubMed: 22334250].
  • 88. Stroh C, Meyer F, Manger T. Beriberi, a severe complication after metabolic surgery - review of the literature. Obes Facts. 2014;7(4):246-52. doi: 10.1159/000366012. [PubMed: 25095897]. [PubMed Central: PMC5644786].
  • 89. Dirani M, Chahine E, Dirani M, Kassir R, Chouillard E. More than a case report? Should wernicke encephalopathy after sleeve gastrectomy be a concern? Obes Surg. 2017;27(10):2684-7. doi: 10.1007/s11695-017-2823-2. [PubMed: 28733807].
  • 90. Ralki M, Cassiman D, Van Dongen J, Ferrante M, Van Overbeke L. Liver failure after long-limb gastric bypass. Clin Res Hepatol Gastroenterol. 2017;41(3):e32-7. doi: 10.1016/j.clinre.2016.11.004. [PubMed: 27939909].
  • 91. Motamedi MAK, Rakhshani N, Khalaj A, Barzin M. Biopsy-proven progressive fatty liver disease nine months post mini-gastric bypass surgery: A case study. Int J Surg Case Rep. 2017;39:168-71. doi: 10.1016/j.ijscr.2017.07.062. [PubMed: 28846948]. [PubMed Central: PMC5573786].
  • 92. Baltasar A. Liver failure and transplantation after duodenal switch. Surg Obes Relat Dis. 2014;10(6):e93-6. doi: 10.1016/j.soard.2014.02.013. [PubMed: 24916757].
  • 93. Baltasar A, Bou R, Bengochea M. Fatal perforations in laparoscopic bowel lengthening operations for malnutrition. Surg Obes Relat Dis. 2010;6(5):572-4. doi: 10.1016/j.soard.2009.12.004. [PubMed: 20176511].
  • 94. Geerts A, Darius T, Chapelle T, Roeyen G, Francque S, Libbrecht L, et al. The multicenter Belgian survey on liver transplantation for hepatocellular failure after bariatric surgery. Transplant Proc. 2010;42(10):4395-8. doi: 10.1016/j.transproceed.2010.07.010. [PubMed: 21168706].
  • 95. Lefere S, Hoorens A, Raevens S, Troisi R, Verhelst X, Van Vlierberghe H, et al. Refractory subacute steatohepatitis after biliopancreatic diversion. Hepatology. 2017;66(1):289-91. doi: 10.1002/hep.29038. [PubMed: 28073162].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments